A Step Forward in Treating Pleural Mesothelioma: The Pembrolizumab and Lenvatinib Combination
|

A Step Forward in Treating Pleural Mesothelioma: The Pembrolizumab and Lenvatinib Combination

Pleural mesothelioma is a rare and aggressive cancer that has been challenging to treat effectively. However, recent breakthroughs in medical research are shedding new light on potential treatment options. Researchers investigated the potential of a combination therapy involving pembrolizumab and lenvatinib. Their findings were promising, with over 50% of patients experiencing tumor shrinkage. While this marks an important step forward, challenges such as side effects need to be carefully addressed in future research. Uncovering Hope for Pleural Mesothelioma Pleural mesothelioma is a rare and aggressive form of cancer that affects the lining of the lungs. It’s linked to exposure to a harmful substance called asbestos. Asbestos used to be used a lot in construction and other industries. Finding good treatments…